Navigation Links
Hard to Treat Diseases (HTDS) Closes 1 Million Dollar Contract Indian Pharmaceutical
Date:11/30/2009

SHENZHEN, China, Nov. 30 /PRNewswire-FirstCall/ - Hard to Treat Diseases' (HTDS; http://www.htdsmedical.com/) operating subsidiary Mellow Hope finalized contract details with one of the largest manufacturer of intravenous medication in India. This contract promises additional increase in revenues for Hard to Treat Diseases in the following quarters.

The contract between HTDS and the Indian company secures the supply of raw pharmaceutical material to the Indian pharmaceutical company in the range of about 1 million USD. Mellow Hope will be ready to release the shipments shortly. This contract is bound to strengthen Mellow Hope's sales and further increase the value of HTDS.

HTDS' CEO Terry Yuan said, "With our earlier, 4 million USD deal with Indian Hetero Ltd. and our H1N1 vaccine deal with Chile, this is another great news for HTDS. Our business has truly grown in past few months and the investors must appreciate our achievements. With the world growing smaller and smaller, the vaccination market and industry are bound to grow bigger. That's the global trend, and HTDS is definitely a part of it."

Hard to Treat Diseases (HTDS) is also a parent company with operations in Serbia based Slavica Biochem www.slavicabiochem.com. This company focuses on the enhancement and modification of existing and approved medications as well as on cancer research. The MindUp cancer research http://www.mindupbioresearch.com has been delivering groundbreaking results on the international level. The company expects to make some significant news announcement with a separate unrelated pharmaceutical company on this shortly.

To receive future updates, via email including quarterly newsletters and company updates which may not be newsworthy however important to the reader and followers of the company please sign up today free at www.minamargroup.com/updates

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters,www.minamargroup.com

SOURCE Hard to Treat Diseases


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Parent training key to improved treatment of behavior problems in children with autism
2. Tailor-made HIV/AIDS treatment closer to reality
3. Natural Soy Component May Help Treat Colon Cancer
4. Cetuximab Helps Treat Colorectal Cancer
5. One Step Closer to New Diabetes Treatment
6. Novel Technology in Treating Chronic Sinus Infections Available at Baptist
7. Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain
8. Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger
9. Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment
10. Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery
11. Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Arizona (PRWEB) , ... December 07, 2016 , ... Delete® ... Just in Time For The Holiday Party Season. Save Up To 33% Off Botox® ... Laser Salon is providing the Phoenix Valley with Delightful Deals on Botox® ...
(Date:12/7/2016)... ... , ... The medical profession is well aware that heart attacks do indeed ... heart attacks among 138,602 people recorded a 35% higher number of heart attacks in ... of course–no time of year is a good time for a heart attack! In ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... medicine device WellnessPro Plus for consumers and healthcare professionals to manage chronic ... by expanding the treatment modalities available in a single device. The announcement ...
(Date:12/7/2016)... ... 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a brief but ... presidency and to America. “Tomorrow Trump Goes To Washington” is the creation of published ... for this country. , Nancy attributes her patriotic nature to her WWII veteran father. ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... ... individuals impacted by cerebral cavernous angiomas, was awarded a grant from the Julian ... engagement program. New Mexico has more people with cavernous angioma than anywhere in ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Homozygous Familial Hypercholesterolemia (HoFH) - ... Global Markets Direct,s latest Pharmaceutical and Healthcare ... – Pipeline Review, H2 2016, provides an ... (Metabolic Disorders) pipeline landscape. Homozygous familial ... caused due to mutation from both parents. ...
(Date:12/6/2016)... The pen needles market is projected to reach USD ... 2016, growing at a CAGR of 11.2% during the ... years, the pen needles market has witnessed various technological ... for safety injections in the healthcare industry. These advancements ... with an aim to reduce pain, increase comfort, and ...
(Date:12/6/2016)... 2016   AlloSource , one of the ... and soft-tissue allografts for use in surgical procedures, ... for being named to the Board of Examiners ... by the Commerce Department,s National Institute of Standards ... process excellence. The Baldrige Award is the nation,s ...
Breaking Medicine Technology: